Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4T reveals microvascular impact of α1-adrenergic receptor antibodies

NMR in Biomedicine

Volumn 27, Issue 9, 2014, Pages 1085-1093

  Pohlmann, Andreas ^a   Karczewski, Peter ^b   Ku, Min Chi ^a   Dieringer, Babette ^a   Waiczies, Helmar ^a   Wisbrun, Natali ^c   Kox, Stefanie ^a   Palatnik, Irina ^a   Reimann, Henning Matthias ^a   Eichhorn, Christina ^a   Waiczies, Sonia ^a   Hempel, Petra ^b   Lemke, Bernd ^b   Niendorf, Thoralf ^a   Bimmler, Marion ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b ERDE AAK Diagnostik GmbH   (Germany)

^c LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

Author keywords

Cerebral blood volume (CBV); Ferumoxytol; MRI; Rat; Ultrasmall superparamagnetic iron oxide (USPIO)

Indexed keywords

BLOOD VESSELS; BRAIN; HEMODYNAMICS; IRON OXIDES; MAGNETIC RESONANCE IMAGING; MAMMALS; NEURODEGENERATIVE DISEASES; NEUROIMAGING; RATING;

ADRENERGIC RECEPTORS; CEREBRAL BLOOD VOLUME; CEREBRAL BLOOD VOLUME(CBV); CEREBROVASCULAR DISEASE; FERUMOXYTOL; IRON OXIDE PARTICLES; TRANSVERSE RELAXATION RATE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANTIBODIES;

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR ANTIBODY; FERUMOXYTOL; IMMUNOGLOBULIN G ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ALPHA 1 ADRENERGIC RECEPTOR; AUTOANTIBODY; CONTRAST MEDIUM; MAGNETITE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; BRAIN BLOOD VESSEL; BRAIN BLOOD VOLUME; BRAIN CORTEX; BRAIN MAPPING; CAPILLARY DENSITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; FEASIBILITY STUDY; HIPPOCAMPUS; IMMUNOHISTOLOGY; MALE; MICROVASCULATURE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARTICLE SIZE; PRIORITY JOURNAL; RAT; RELAXATION TIME; STEADY STATE; ANIMAL; BLOOD FLOW VELOCITY; BLOOD VOLUME; BRAIN CIRCULATION; DIAGNOSTIC USE; IMMUNOLOGY; MAGNETIC RESONANCE ANGIOGRAPHY; PATHOLOGY; PROCEDURES; WISTAR RAT;

RATTUS; RODENTIA;

ANIMALS; AUTOANTIBODIES; BLOOD FLOW VELOCITY; BLOOD VOLUME; BLOOD VOLUME DETERMINATION; CEREBROVASCULAR CIRCULATION; CONTRAST MEDIA; FERROSOFERRIC OXIDE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICROVESSELS; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 84905914401     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3160     Document Type: Article

References (39)

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010; 9(7): 689-701.
2. Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, Van Deerlin V, Lee VM, Trojanowski JQ, Arnold SE. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 2012; 135(Pt 12): 3749-3756.
3. Hunter JM, Kwan J, Malek-Ahmadi M, Maarouf CL, Kokjohn TA, Belden C, Sabbagh MN, Beach TG, Roher AE. Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease. PLoS One 2012; 7(5): e36893.
4. Fu ML, Herlitz H, Wallukat G, Hilme E, Hedner T, Hoebeke J, Hjalmarson A. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension. Lancet 1994; 344(8938): 1660-1663.
5. Yan L, Xu Y, Yao H, Xue W, Tian J, Ren H, Wu Y, Yang G, Ma XL, Liu H. The effects of autoantibodies against the second extracellular loop of alpha(1)-adrenoceptor on vasoconstriction. Basic Res. Cardiol. 2009; 104(5): 581-589.
6. Karczewski P, Hempel P, Kunze R, Bimmler M. Agonistic autoantibodies to the alpha(1)-adrenergic receptor and the beta(2)-adrenergic receptor in Alzheimer's and vascular dementia. Scand. J. Immunol. 2012; 75(5): 524-530.
7. Zhou Z, Liao Y, Li L, Wei F, Wang B, Wei Y, Wang M, Cheng X. Vascular damages in rats immunized by alpha1-adrenoceptor peptides. Cell. Mol. Immunol. 2008; 5(5): 349-356.
8. Wenzel K, Haase H, Wallukat G, Derer W, Bartel S, Homuth V, Herse F, Hubner N, Schulz H, Janczikowski M, Lindschau C, Schroeder C, Verlohren S, Morano I, Muller DN, Luft FC, Dietz R, Dechend R, Karczewski P. Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension. PLoS One 2008; 3(11): e3742.
9. Xia Y, Kellems RE. Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev. Clin. Immunol. 2011; 7(5): 659-674.
10. O'Neill C, Fowler CJ, Marcusson JO, Winblad B. Adrenergic, serotoninergic, histaminergic, and imipramine binding sites in post-mortal human cerebral microvessel preparations. J. Neural Transm. 1988; 73(3): 177-189.
11. Karczewski P, Pohlmann A, Wagenhaus B, Wisbrun N, Hempel P, Lemke B, Kunze R, Niendorf T, Bimmler M. Antibodies to the alpha1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One 2012; 7(7): e41602.
12. Zaharchuk G. Theoretical basis of hemodynamic MR imaging techniques to measure cerebral blood volume, cerebral blood flow, and permeability. Am. J. Neuroradiol. 2007; 28(10): 1850-1858.
13. Christen T, Ni W, Qiu D, Schmiedeskamp H, Bammer R, Moseley M, Zaharchuk G. High-resolution cerebral blood volume imaging in humans using the blood pool contrast agent ferumoxytol. Magn. Reson. Med. 2013; 70(3): 705-710.
14. Kim SG, Harel N, Jin T, Kim T, Lee P, Zhao F. Cerebral blood volume MRI with intravascular superparamagnetic iron oxide nanoparticles. NMR Biomed. 2013; 26(8): 949-962.
15. Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, Muldoon LL, Neuwelt EA. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J. Cereb. Blood Flow Metab. 2010; 30(1): 15-35.
16. Gahramanov S, Muldoon LL, Li X, Neuwelt EA. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. Radiology 2011; 261(3): 796-804.
17. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn. Reson. Med. 1995; 34(4): 555-566.
18. Mandeville JB, Marota JJ, Kosofsky BE, Keltner JR, Weissleder R, Rosen BR, Weisskoff RM. Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn. Reson. Med. 1998; 39(4): 615-624.
19. Weisskoff RM, Zuo CS, Boxerman JL, Rosen BR. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn. Reson. Med. 1994; 31(6): 601-610.
20. Shi Q, Pisani LJ, Lee YK, Messing S, Ansari C, Bhaumik S, Lowery L, Lee BD, Meyer DE, Daldrup-Link HE. Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses. Contrast Media Mol. Imaging 2013; 8(3): 281-288.
21. Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol. 2010; 85(5): 315-319.
22. Pannetier N, Lemasson B, Christen T, Tachrount M, Tropres I, Farion R, Segebarth C, Remy C, Barbier EL. Vessel size index measurements in a rat model of glioma: comparison of the dynamic (Gd) and steady-state (iron-oxide) susceptibility contrast MRI approaches. NMR Biomed. 2012; 25(2): 218-226.
23. Qiu D, Zaharchuk G, Christen T, Ni WW, Moseley ME. Contrast-enhanced functional blood volume imaging (CE-fBVI): enhanced sensitivity for brain activation in humans using the ultrasmall superparamagnetic iron oxide agent ferumoxytol. Neuroimage 2012; 62(3): 1726-1731.
24. Varallyay CG, Nesbit E, Fu R, Gahramanov S, Moloney B, Earl E, Muldoon LL, Li X, Rooney WD, Neuwelt EA. High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle. J. Cereb. Blood Flow Metab. 2013; 33(5): 780-786.
25. Thompson EM, Guillaume DJ, Dosa E, Li X, Nazemi KJ, Gahramanov S, Hamilton BE, Neuwelt EA. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. J. Neurooncol 2012; 109(1): 105-114.
26. Farrell BT, Hamilton BE, Dosa E, Rimely E, Nasseri M, Gahramanov S, Lacy CA, Frenkel EP, Doolittle ND, Jacobs PM, Neuwelt EA. Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. Neurology 2013; 81(3): 256-263.
27. Muldoon LL, Gahramanov S, Li X, Marshall DJ, Kraemer DF, Neuwelt EA. Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. Neuro-Oncology 2011; 13(1): 51-60.
28. Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, Li X, Pike MM, Neuwelt EA. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J. Cereb. Blood Flow Metab. 2009; 29(4): 853-860.
29. Muldoon LL, Sandor M, Pinkston KE, Neuwelt EA. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery 2005; 57(4): 785-796; discussion 785-796.
30. Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, Lamalle L, Decorps M. Vessel size imaging. Magn. Reson. Med. 2001; 45(3): 397-408.
31. Mandeville JB. IRON fMRI measurements of CBV and implications for BOLD signal. Neuroimage 2012; 62(2): 1000-1008.
32. Sirvio J, MacDonald E. Central alpha1-adrenoceptors: their role in the modulation of attention and memory formation. Pharmacol. Ther. 1999; 83(1): 49-65.
33. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Alpha1-adrenoreceptor in human hippocampus: binding and receptor subtype mRNA expression. Brain Res. Mol. Brain Res. 2005; 139(2): 367-371.
34. Lopez OL, Rabin BS, Huff FJ, Rezek D, Reinmuth OM. Serum autoantibodies in patients with Alzheimer's disease and vascular dementia and in nondemented control subjects. Stroke 1992; 23(8): 1078-1083.
35. Boehm-Sturm P, Farr TD, Adamczak J, Jikeli JF, Mengler L, Wiedermann D, Kallur T, Kiselev V, Hoehn M. Vascular changes after stroke in the rat: a longitudinal study using optimized magnetic resonance imaging. Contrast Media Mol. Imaging 2013; 8(5): 383-392.
36. Perkkio J, Keskinen R. Hematocrit reduction in bifurcations due to plasma skimming. Bull. Math. Biol. 1983; 45(1): 41-50.
37. Matta BF, Heath KJ, Tipping K, Summors AC. Direct cerebral vasodilatory effects of sevoflurane and isoflurane. Anesthesiology 1999; 91(3): 677-680.
38. Hendrich KS, Kochanek PM, Melick JA, Schiding JK, Statler KD, Williams DS, Marion DW, Ho C. Cerebral perfusion during anesthesia with fentanyl, isoflurane, or pentobarbital in normal rats studied by arterial spin-labeled MRI. Magn. Reson. Med. 2001; 46(1): 202-206.
39. Lee HB, Blaufox MD. Blood volume in the rat. J. Nucl. Med. 1985; 26(1): 72-76.